Erbitux Colon Cancer Data “Encouraging,” ImClone Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Following mixed results from two Phase III trials, the company plans to consult FDA on next steps.
You may also be interested in...
FDA Panel Views On PFS Endpoint For Avastin Could Impact Fate Of Other First-Line Cancer Drugs
Panel’s rejection of Genentech sBLA for first-line breast cancer despite meeting endpoint of progression-free survival leaves Wall Street wondering if same fate will befall ImClone/Bristol’s Erbitux in colon cancer.
FDA Panel Views On PFS Endpoint For Avastin Could Impact Fate Of Other First-Line Cancer Drugs
Panel’s rejection of Genentech sBLA for first-line breast cancer despite meeting endpoint of progression-free survival leaves Wall Street wondering if same fate will befall ImClone/Bristol’s Erbitux in colon cancer.
ImClone Reports Promising Erbitux First-Line Colorectal Cancer Results
Company will present data from the Phase III CRYSTAL study at ASCO in June.